Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation.

Lung cancer (Amsterdam, Netherlands) - 1 Jan 2020

Zhou Fei, Zhao Wencheng, Chen Xiaoxia, Zhang Jie, Zhou Caicun

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Imidazoles
Share to Liquid Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Source

Identifiers

PMID: 31640894
DOI: 10.1016/j.lungcan.2019.10.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation.PMID 31640894Read ↗

Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation.Semantic proximity Read ↗

Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations.Semantic proximity Read ↗

Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.Semantic proximity Read ↗

Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.Semantic proximity Read ↗

Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAFV600 mutation as an acquired resistance mechanism.Semantic proximity Read ↗

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Semantic proximity Read ↗

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case ReportSemantic proximity Read ↗

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.Semantic proximity Read ↗

Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience.Semantic proximity Read ↗

Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.